SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on January 7, 2015. The report serves as a Regulation FD disclosure, furnishing a press release dated January 7, 2015 (Exhibit 99.1). The registrant is incorporated in Delaware with principal executive offices in Louisville, CO.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose a press release and does not contain audited financial statements or detailed financial data.
Material Changes
The filing does not detail specific material changes to financial performance or operations within the text provided. It solely references the issuance of a press release as the event being reported.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and specific risk factors are contained within the attached press release (Exhibit 99.1), which is not included in the provided text. The filing explicitly states that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the content of the press release (Exhibit 99.1) to understand the specific event triggering this disclosure.
- Note that the registrant name in the filing is AntriaBio, Inc., despite the request metadata referencing Rezolute, Inc.
- Confirm that no financial metrics are disclosed in this specific 8-K text; investors must refer to the attached exhibit or other periodic reports for financial data.